<ul>
<li>Myriad Genetics 股票因遗传性癌症检测而大幅上涨</li>
</ul>
<p>Quest Diagnostics Incorporated (NYSE:DGX - 免费报告) - Leerink Partnrs 在 10 月 21 日星期二向投资者发布的报告中下调了对 Quest Diagnostics 2025 财年第四季度每股收益的预期。Leerink Partnrs 分析师 M. Cherny 现在预计该医疗研究公司本季度每股收益为 2.39 美元，低于之前的 2.45 美元预期。Quest Diagnostics 当前全年的共识每股收益预期为 9.70 美元。</p>
<p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
<p>其他一些券商也对 DGX 发表了评论。摩根士丹利在周三的研究报告中将 Quest Diagnostics 的目标股价设定为 207.00 美元，并给予该公司 “增持” 评级。瑞穗证券在 10 月 17 日星期五将 Quest Diagnostics 的目标股价从 190.00 美元上调至 210.00 美元，并给予该公司 “跑赢大盘” 评级。威廉·布莱尔在 7 月 23 日星期三的研究报告中重申了对 Quest Diagnostics 的 “跑赢大盘” 评级。瑞银集团在 10 月 17 日星期五的研究报告中将 Quest Diagnostics 的目标股价从 180.00 美元上调至 190.00 美元，并给予该公司 “中性” 评级。最后，德意志银行在 7 月 23 日星期三的研究报告中将 Quest Diagnostics 的目标股价从 160.00 美元上调至 178.00 美元，并给予该公司 “持有” 评级。一位分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，十位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 196.31 美元。</p>
<ul>
<li>LifeMD 股票因 GLP-1 业务增长而复苏</li>
</ul>
<p><strong>获取我们关于 DGX 的最新报告</strong></p>
<h2>Quest Diagnostics 股票上涨 1.2%</h2>
<p>DGX 股票在周五以 183.29 美元开盘。Quest Diagnostics 的 52 周低点为 148.70 美元，52 周高点为 197.55 美元。该公司的市值为 203.9 亿美元，市盈率为 21.51，市盈率增长比率为 2.39，贝塔值为 0.56。该公司的 50 日简单移动平均线为 182.94 美元，200 日简单移动平均线为 176.62 美元。该公司的债务与股本比率为 0.71，速动比率为 0.99，流动比率为 1.13。</p>
<ul>
<li>Exact Sciences 准确满足投资者的期望</li>
</ul>
<p>Quest Diagnostics (NYSE:DGX - 获取免费报告) 最近在 10 月 21 日星期二公布了季度财报。该医疗研究公司报告本季度每股收益为 2.60 美元，超出分析师共识预期的 2.51 美元，超出幅度为 0.09 美元。Quest Diagnostics 的净利润率为 8.91%，股本回报率为 15.47%。该公司本季度的收入为 28.2 亿美元，而分析师预期为 27.3 亿美元。在去年同期，该公司每股收益为 2.30 美元。Quest Diagnostics 的季度收入同比增长 13.2%。Quest Diagnostics 已将其 2025 财年的指导目标设定为 9.760-9.840 每股收益。</p>
<h2>Quest Diagnostics 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 10 月 20 日星期一支付。10 月 3 日星期五的股东获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，分红收益率为 1.7%。除息日期为 10 月 3 日星期五。Quest Diagnostics 的分红支付比率目前为 38.32%。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，高级副总裁 Michael E. Prevoznik 于 9 月 23 日星期二出售了 28,288 股公司的股票。股票以平均价格 187.12 美元出售，总交易额为 5,293,250.56 美元。出售完成后，该高级副总裁持有 38,117 股公司的股票，价值约为 7,132,453.04 美元。这代表其持股比例减少了 42.60%。该交易在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，高级副总裁 Patrick Plewman 于 8 月 6 日星期三出售了 5,535 股公司的股票。该股票以平均价格 175.00 美元出售，总交易额为 968,625.00 美元。出售后，该高级副总裁直接持有 19,219 股公司的股票，价值约为 3,363,325 美元。该交易代表其持股比例减少了 22.36%。该交易的披露信息可以在此找到。内部人士在上个季度共出售了价值 9,647,471 美元的 53,186 股公司股票。公司内部人士持有公司股票的 8.16%。</p>
<h2>Quest Diagnostics 的机构交易</h2>
<p>一些机构投资者和对冲基金最近对该公司的持仓进行了调整。俄勒冈州公共雇员退休基金在第三季度将其在 Quest Diagnostics 的持股增加了 32.1%。俄勒冈州公共雇员退休基金目前拥有 12,763 股该医疗研究公司的股票，价值 2,432,000 美元，在此期间又增持了 3,100 股。Nisa Investment Advisors LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 61.8%。Nisa Investment Advisors LLC 目前拥有 18,050 股该医疗研究公司的股票，价值 3,440,000 美元，在此期间又增持了 6,892 股。G&amp;S Capital LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 117.1%。G&amp;S Capital LLC 目前拥有 15,249 股该医疗研究公司的股票，价值 2,906,000 美元，在此期间又增持了 8,225 股。Steigerwald Gordon &amp; Koch Inc.在第三季度购买了 Quest Diagnostics 的新股份，价值约 47,000 美元。最后，Benjamin Edwards Inc.在第三季度将其在 Quest Diagnostics 的持股增加了 2.1%。Benjamin Edwards Inc.目前拥有 6,891 股该医疗研究公司的股票，价值 1,313,000 美元，在此期间又增持了 140 股。机构投资者持有该公司 88.06% 的股票。</p>
<h2>Quest Diagnostics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，包括常规、非常规和高级临床测试、解剖病理测试及其他诊断信息服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Quest Diagnostics</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>华纳兄弟竞标战潜力：WBD 股票能涨多高？</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>分析师预计 Netflix 在第三季度财报崩溃后有 30% 的上涨空间</li>
<li>风险承受能力因人而异</li>
<li>O’Reilly Automotive 的股票价格上升趋势将在 2026 年继续</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Quest Diagnostics 吗？</h2>
<p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Quest Diagnostics 并不在名单上。</p>
<p>虽然 Quest Diagnostics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奎斯特诊疗

<p>Leerink Partners 将 Quest Diagnostics (NYSE:DGX) 2025 年第四季度每股收益（EPS）预估从 $2.45 下调至 $2.39。市场对该公司全年收益的共识预估为每股 $9.70。多家券商对 DGX 设置了目标价，其中摩根士丹利为 $207.00，瑞穗为 $210.00。Quest Diagnostics 最近报告的季度每股收益为 $2.60，超出预期，并宣布季度股息为每股 $0.80。该股开盘价为 $183.29，市值为 $203.9 亿，市盈率为 21.51</p>

<ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 股票因遗传性癌症检测而大幅上涨</li>
</ul>
</div><p>Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Leerink Partnrs reduced their Q4 2025 EPS estimates for shares of Quest Diagnostics in a note issued to investors on Tuesday, October 21st. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.39 per share for the quarter, down from their prior estimate of $2.45. The consensus estimate for Quest Diagnostics' current full-year earnings is $9.70 per share.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated (NYSE:DGX - 免费报告) - Leerink Partnrs 在 10 月 21 日星期二向投资者发布的报告中下调了对 Quest Diagnostics 2025 财年第四季度每股收益的预期。Leerink Partnrs 分析师 M. Cherny 现在预计该医疗研究公司本季度每股收益为 2.39 美元，低于之前的 2.45 美元预期。Quest Diagnostics 当前全年的共识每股收益预期为 9.70 美元。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
</div><p>A number of other brokerages have also commented on DGX. Morgan Stanley set a $207.00 price target on shares of Quest Diagnostics and gave the company an &#34;overweight&#34; rating in a research note on Wednesday. Mizuho upped their price target on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, October 17th. William Blair reiterated an &#34;outperform&#34; rating on shares of Quest Diagnostics in a research note on Wednesday, July 23rd. UBS Group upped their price target on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, October 17th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Quest Diagnostics from $160.00 to $178.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $196.31.</p>
<div class="lb-trans"><p>其他一些券商也对 DGX 发表了评论。摩根士丹利在周三的研究报告中将 Quest Diagnostics 的目标股价设定为 207.00 美元，并给予该公司 “增持” 评级。瑞穗证券在 10 月 17 日星期五将 Quest Diagnostics 的目标股价从 190.00 美元上调至 210.00 美元，并给予该公司 “跑赢大盘” 评级。威廉·布莱尔在 7 月 23 日星期三的研究报告中重申了对 Quest Diagnostics 的 “跑赢大盘” 评级。瑞银集团在 10 月 17 日星期五的研究报告中将 Quest Diagnostics 的目标股价从 180.00 美元上调至 190.00 美元，并给予该公司 “中性” 评级。最后，德意志银行在 7 月 23 日星期三的研究报告中将 Quest Diagnostics 的目标股价从 160.00 美元上调至 178.00 美元，并给予该公司 “持有” 评级。一位分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，十位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 196.31 美元。</p>
</div><ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 股票因 GLP-1 业务增长而复苏</li>
</ul>
</div><p><strong>Get Our Latest Report on DGX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 DGX 的最新报告</strong></p>
</div><h2>Quest Diagnostics Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股票上涨 1.2%</h2>
</div><p>Shares of DGX opened at $183.29 on Friday. Quest Diagnostics has a 52 week low of $148.70 and a 52 week high of $197.55. The firm has a market cap of $20.39 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 2.39 and a beta of 0.56. The firm's 50-day simple moving average is $182.94 and its 200 day simple moving average is $176.62. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.99 and a current ratio of 1.13.</p>
<div class="lb-trans"><p>DGX 股票在周五以 183.29 美元开盘。Quest Diagnostics 的 52 周低点为 148.70 美元，52 周高点为 197.55 美元。该公司的市值为 203.9 亿美元，市盈率为 21.51，市盈率增长比率为 2.39，贝塔值为 0.56。该公司的 50 日简单移动平均线为 182.94 美元，200 日简单移动平均线为 176.62 美元。该公司的债务与股本比率为 0.71，速动比率为 0.99，流动比率为 1.13。</p>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>Exact Sciences 准确满足投资者的期望</li>
</ul>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, beating analysts' consensus estimates of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter in the prior year, the business earned $2.30 EPS. Quest Diagnostics's quarterly revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS.</p>
<div class="lb-trans"><p>Quest Diagnostics (NYSE:DGX - 获取免费报告) 最近在 10 月 21 日星期二公布了季度财报。该医疗研究公司报告本季度每股收益为 2.60 美元，超出分析师共识预期的 2.51 美元，超出幅度为 0.09 美元。Quest Diagnostics 的净利润率为 8.91%，股本回报率为 15.47%。该公司本季度的收入为 28.2 亿美元，而分析师预期为 27.3 亿美元。在去年同期，该公司每股收益为 2.30 美元。Quest Diagnostics 的季度收入同比增长 13.2%。Quest Diagnostics 已将其 2025 财年的指导目标设定为 9.760-9.840 每股收益。</p>
</div><h2>Quest Diagnostics Announces Dividend</h2>
<div class="lb-trans"><h2>Quest Diagnostics 宣布分红</h2>
</div><p>The firm also recently announced a quarterly dividend, which was paid on Monday, October 20th. Shareholders of record on Friday, October 3rd were given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, October 3rd. Quest Diagnostics's dividend payout ratio is presently 38.32%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 10 月 20 日星期一支付。10 月 3 日星期五的股东获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，分红收益率为 1.7%。除息日期为 10 月 3 日星期五。Quest Diagnostics 的分红支付比率目前为 38.32%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, SVP Michael E. Prevoznik sold 28,288 shares of the company's stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total transaction of $5,293,250.56. Following the completion of the sale, the senior vice president owned 38,117 shares of the company's stock, valued at approximately $7,132,453.04. This represents a 42.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Patrick Plewman sold 5,535 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $175.00, for a total transaction of $968,625.00. Following the sale, the senior vice president directly owned 19,219 shares of the company's stock, valued at approximately $3,363,325. This trade represents a 22.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,186 shares of company stock worth $9,647,471 in the last quarter. Corporate insiders own 8.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，高级副总裁 Michael E. Prevoznik 于 9 月 23 日星期二出售了 28,288 股公司的股票。股票以平均价格 187.12 美元出售，总交易额为 5,293,250.56 美元。出售完成后，该高级副总裁持有 38,117 股公司的股票，价值约为 7,132,453.04 美元。这代表其持股比例减少了 42.60%。该交易在向 SEC 提交的法律文件中披露，文件可通过此链接访问。此外，高级副总裁 Patrick Plewman 于 8 月 6 日星期三出售了 5,535 股公司的股票。该股票以平均价格 175.00 美元出售，总交易额为 968,625.00 美元。出售后，该高级副总裁直接持有 19,219 股公司的股票，价值约为 3,363,325 美元。该交易代表其持股比例减少了 22.36%。该交易的披露信息可以在此找到。内部人士在上个季度共出售了价值 9,647,471 美元的 53,186 股公司股票。公司内部人士持有公司股票的 8.16%。</p>
</div><h2>Institutional Trading of Quest Diagnostics</h2>
<div class="lb-trans"><h2>Quest Diagnostics 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund lifted its holdings in shares of Quest Diagnostics by 32.1% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 12,763 shares of the medical research company's stock worth $2,432,000 after acquiring an additional 3,100 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Quest Diagnostics by 61.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,050 shares of the medical research company's stock worth $3,440,000 after acquiring an additional 6,892 shares during the period. G&amp;S Capital LLC lifted its holdings in shares of Quest Diagnostics by 117.1% during the 3rd quarter. G&amp;S Capital LLC now owns 15,249 shares of the medical research company's stock worth $2,906,000 after acquiring an additional 8,225 shares during the period. Steigerwald Gordon &amp; Koch Inc. bought a new stake in shares of Quest Diagnostics during the 3rd quarter worth approximately $47,000. Finally, Benjamin Edwards Inc. lifted its holdings in shares of Quest Diagnostics by 2.1% during the 3rd quarter. Benjamin Edwards Inc. now owns 6,891 shares of the medical research company's stock worth $1,313,000 after acquiring an additional 140 shares during the period. Institutional investors own 88.06% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近对该公司的持仓进行了调整。俄勒冈州公共雇员退休基金在第三季度将其在 Quest Diagnostics 的持股增加了 32.1%。俄勒冈州公共雇员退休基金目前拥有 12,763 股该医疗研究公司的股票，价值 2,432,000 美元，在此期间又增持了 3,100 股。Nisa Investment Advisors LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 61.8%。Nisa Investment Advisors LLC 目前拥有 18,050 股该医疗研究公司的股票，价值 3,440,000 美元，在此期间又增持了 6,892 股。G&amp;S Capital LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 117.1%。G&amp;S Capital LLC 目前拥有 15,249 股该医疗研究公司的股票，价值 2,906,000 美元，在此期间又增持了 8,225 股。Steigerwald Gordon &amp; Koch Inc.在第三季度购买了 Quest Diagnostics 的新股份，价值约 47,000 美元。最后，Benjamin Edwards Inc.在第三季度将其在 Quest Diagnostics 的持股增加了 2.1%。Benjamin Edwards Inc.目前拥有 6,891 股该医疗研究公司的股票，价值 1,313,000 美元，在此期间又增持了 140 股。机构投资者持有该公司 88.06% 的股票。</p>
</div><h2>Quest Diagnostics Company Profile</h2>
<div class="lb-trans"><h2>Quest Diagnostics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，包括常规、非常规和高级临床测试、解剖病理测试及其他诊断信息服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Warner Bros. Bidding War Potential: How High Could WBD Shares Go?</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>Analysts Eye 30% Upside in Netflix After Q3 Earnings Crash</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>O’Reilly Automotive’s Stock Price Uptrend Will Continue in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Quest Diagnostics</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>华纳兄弟竞标战潜力：WBD 股票能涨多高？</li>
<li>上升趋势股票解析：学习如何利用上升趋势进行交易</li>
<li>分析师预计 Netflix 在第三季度财报崩溃后有 30% 的上涨空间</li>
<li>风险承受能力因人而异</li>
<li>O’Reilly Automotive 的股票价格上升趋势将在 2026 年继续</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Quest Diagnostics 吗？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Quest Diagnostics 并不在名单上。</p>
</div><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Quest Diagnostics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Leerink Partners 对奎斯特诊疗的收益发布了悲观的估计